blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2595959

EP2595959 - SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.09.2016
Database last updated on 23.04.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2015/45]
Former [2013/22]For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
Inventor(s)01 / HICKEY, Eugene Richard
c/o VP, IP, Legal, Boehringer Ingelheim USA Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
02 / RIETHER, Doris
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
03 / ERMANN, Monika
114 Milton Park
Abingdon Oxfordshire OX14 4SA / GB
 [2013/22]
Representative(s)Simon, Elke Anna Maria, et al
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2015/45]
Former [2013/22]Simon, Elke Anna Maria, et al
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
Application number, filing date11740762.718.07.2011
[2015/45]
WO2011US44309
Priority number, dateUS20100366660P22.07.2010         Original published format: US 366660 P
[2013/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012012307
Date:26.01.2012
Language:EN
[2012/04]
Type: A1 Application with search report 
No.:EP2595959
Date:29.05.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 26.01.2012 takes the place of the publication of the European patent application.
[2013/22]
Type: B1 Patent specification 
No.:EP2595959
Date:04.11.2015
Language:EN
[2015/45]
Search report(s)International search report - published on:EP26.01.2012
ClassificationIPC:C07D213/74, C07D231/38, C07D261/14, C07D277/46, C07D413/12, C07D285/135, A61K31/44, A61K31/415, A61K31/41, A61P29/00
[2013/22]
CPC:
C07D285/135 (EP,US); A61P1/00 (EP); A61P1/02 (EP);
A61P11/00 (EP); A61P13/12 (EP); A61P17/00 (EP);
A61P17/02 (EP); A61P19/00 (EP); A61P21/00 (EP);
A61P25/00 (EP); A61P25/04 (EP); A61P27/02 (EP);
A61P27/16 (EP); A61P29/00 (EP); A61P3/00 (EP);
A61P35/00 (EP); A61P37/02 (EP); A61P37/06 (EP);
A61P37/08 (EP); A61P43/00 (EP); A61P7/00 (EP);
A61P9/00 (EP); A61P9/04 (EP); A61P9/10 (EP);
C07D213/74 (EP,US); C07D231/38 (EP,US); C07D261/14 (EP,US);
C07D261/18 (EP,US); C07D277/46 (EP,US); C07D413/12 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/22]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:SULFONYLVERBINDUNGEN ZUR MODULIERUNG DES CB2-REZEPTORS[2013/22]
English:SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR[2013/22]
French:COMPOSÉS SULFONYLÉS QUI MODULENT LE RÉCEPTEUR CB2[2013/22]
Entry into regional phase22.02.2013National basic fee paid 
22.02.2013Designation fee(s) paid 
22.02.2013Examination fee paid 
Examination procedure16.01.2013Amendment by applicant (claims and/or description)
22.02.2013Examination requested  [2013/22]
06.02.2014Despatch of a communication from the examining division (Time limit: M04)
27.05.2014Reply to a communication from the examining division
23.06.2014Despatch of a communication from the examining division (Time limit: M04)
14.10.2014Reply to a communication from the examining division
15.01.2015Despatch of a communication from the examining division (Time limit: M04)
23.04.2015Reply to a communication from the examining division
03.06.2015Communication of intention to grant the patent
17.09.2015Fee for grant paid
17.09.2015Fee for publishing/printing paid
17.09.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  06.02.2014
Opposition(s)05.08.2016No opposition filed within time limit [2016/41]
Fees paidRenewal fee
31.07.2013Renewal fee patent year 03
31.07.2014Renewal fee patent year 04
31.07.2015Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.07.2011
AL04.11.2015
AT04.11.2015
BE04.11.2015
BG04.11.2015
CY04.11.2015
CZ04.11.2015
DK04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
MC04.11.2015
MK04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SI04.11.2015
SK04.11.2015
SM04.11.2015
TR04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
IE18.07.2016
LU18.07.2016
CH31.07.2016
LI31.07.2016
MT31.07.2016
[2018/46]
Former [2018/38]HU18.07.2011
AT04.11.2015
BE04.11.2015
BG04.11.2015
CY04.11.2015
CZ04.11.2015
DK04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
MC04.11.2015
MK04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SI04.11.2015
SK04.11.2015
SM04.11.2015
TR04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
IE18.07.2016
LU18.07.2016
CH31.07.2016
LI31.07.2016
MT31.07.2016
Former [2018/31]HU18.07.2011
AT04.11.2015
BE04.11.2015
CY04.11.2015
CZ04.11.2015
DK04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
MC04.11.2015
MK04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SI04.11.2015
SK04.11.2015
SM04.11.2015
TR04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
IE18.07.2016
LU18.07.2016
CH31.07.2016
LI31.07.2016
MT31.07.2016
Former [2018/29]HU18.07.2011
AT04.11.2015
BE04.11.2015
CY04.11.2015
CZ04.11.2015
DK04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
MC04.11.2015
MK04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SI04.11.2015
SK04.11.2015
SM04.11.2015
TR04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
IE18.07.2016
LU18.07.2016
CH31.07.2016
LI31.07.2016
Former [2018/28]HU18.07.2011
AT04.11.2015
BE04.11.2015
CY04.11.2015
CZ04.11.2015
DK04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
MC04.11.2015
MK04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SI04.11.2015
SK04.11.2015
SM04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
IE18.07.2016
LU18.07.2016
CH31.07.2016
LI31.07.2016
Former [2017/41]AT04.11.2015
BE04.11.2015
CZ04.11.2015
DK04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
MC04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SI04.11.2015
SK04.11.2015
SM04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
IE18.07.2016
LU18.07.2016
CH31.07.2016
LI31.07.2016
Former [2017/22]AT04.11.2015
BE04.11.2015
CZ04.11.2015
DK04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
MC04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SI04.11.2015
SK04.11.2015
SM04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
CH31.07.2016
LI31.07.2016
Former [2017/03]AT04.11.2015
BE04.11.2015
CZ04.11.2015
DK04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SI04.11.2015
SK04.11.2015
SM04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
Former [2016/49]AT04.11.2015
CZ04.11.2015
DK04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SI04.11.2015
SK04.11.2015
SM04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
Former [2016/39]AT04.11.2015
CZ04.11.2015
DK04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SK04.11.2015
SM04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
Former [2016/38]AT04.11.2015
CZ04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SK04.11.2015
SM04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
Former [2016/36]AT04.11.2015
CZ04.11.2015
EE04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
NL04.11.2015
PL04.11.2015
RO04.11.2015
RS04.11.2015
SE04.11.2015
SK04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
Former [2016/34]AT04.11.2015
CZ04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
NL04.11.2015
PL04.11.2015
RS04.11.2015
SE04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
Former [2016/25]AT04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
LV04.11.2015
NL04.11.2015
PL04.11.2015
RS04.11.2015
SE04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
Former [2016/24]AT04.11.2015
ES04.11.2015
FI04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
NL04.11.2015
PL04.11.2015
RS04.11.2015
SE04.11.2015
NO04.02.2016
GR05.02.2016
IS04.03.2016
PT04.03.2016
Former [2016/23]ES04.11.2015
HR04.11.2015
IT04.11.2015
LT04.11.2015
NL04.11.2015
RS04.11.2015
SE04.11.2015
NO04.02.2016
IS04.03.2016
Former [2016/22]ES04.11.2015
IT04.11.2015
LT04.11.2015
NL04.11.2015
NO04.02.2016
IS04.03.2016
Former [2016/21]ES04.11.2015
IT04.11.2015
LT04.11.2015
NO04.02.2016
Former [2016/20]ES04.11.2015
LT04.11.2015
Cited inInternational search[XP]WO2011035159  (ZALICUS PHARMACEUTICALS LTD [CA], et al) [XP] 1-8,10,24-26 * examples 457,475,476,478,484,485,490,491,493,501,505; claims 1,46,50,78 *;
 [AD]WO2008014199  (BOEHRINGER INGELHEIM INT [DE], et al) [AD] 1-26 * claims 1,12 *;
 [AD]WO2008039645  (BOEHRINGER INGELHEIM INT [DE], et al) [AD] 1-26 * claims 1,14 *
by applicantWO2008014199
 WO2008039645
 WO2008098025
 WO2009061652
 WO9712687
 WO9407607
 WO9712683
 WO9720590
    - ZIMMER ET AL., "Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB receptor knockout mice", PROC NATL ACAD SCI U S A., (1999), vol. 96, doi:doi:10.1073/pnas.96.10.5780, pages 5780 - 5785, XP000982859

DOI:   http://dx.doi.org/10.1073/pnas.96.10.5780
    - KLEIN ET AL., "The cannabinoid system and immune system", J LEUKOC BIOL, (2003), vol. 74, doi:doi:10.1189/jlb.0303101, pages 486 - 496, XP001199700

DOI:   http://dx.doi.org/10.1189/jlb.0303101
    - BICKLET ET AL., "Immunomodulation by cannabinoid is absent in mice deficient for the cannabinoid CB2 receptor", EUR J PHARMACOL, (2000), vol. 396, pages 141 - 149, XP000991066
    - HANUS ET AL., "HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor", PROC NATL ACAD SCI U S A., (1999), vol. 96, doi:doi:10.1073/pnas.96.25.14228, pages 14228 - 14233, XP002638929

DOI:   http://dx.doi.org/10.1073/pnas.96.25.14228
    - UEDA ET AL., "Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice", EUR J PHARMACOL., (2005), vol. 520, doi:doi:10.1016/j.ejphar.2005.08.013, pages 164 - 171, XP005090462

DOI:   http://dx.doi.org/10.1016/j.ejphar.2005.08.013
    - SMITH ET AL., "The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models", EUR J PHARMACOL., (2001), vol. 432, pages 107 - 119
    - BAKER ET AL., "Cannabinoids control spasticity and tremor in a multiple sclerosis model", NATURE, (2000), vol. 404, doi:doi:10.1038/35003583, pages 84 - 87, XP000914618

DOI:   http://dx.doi.org/10.1038/35003583
    - AREVALO-MARTIN ET AL., "Therapeutic action of cannabinoids in a murine model of multiple sclerosis", J NEUROSCI, (2003), vol. 23, pages 2511 - 2516
    - MALAN ET AL., "CB2 cannabinoid receptor-mediated peripheral antinociception", PAIN, (2001), vol. 93, doi:doi:10.1016/S0304-3959(01)00321-9, pages 239 - 45, XP003015145

DOI:   http://dx.doi.org/10.1016/S0304-3959(01)00321-9
    - NACKLEY ET AL., "Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation", NEUROSCIENCE, (2003), vol. 119, pages 747 - 57
    - IBRAHIM ET AL., "Activation of CB2 cannabinoid receptors by AM 1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS", PROC NATL ACAD SCI U S A., (2003), vol. 100, pages 10529 - 33
    - VAN SICKLE ET AL., "Identification and functional characterization of brainstem cannabinoid CB2 receptors", SCIENCE, (2005), vol. 310, pages 329 - 332
    - RADZISZEWSKI, J.G. ET AL., J. AM. CHEM SOC., (1993), vol. 115, page 8401
    - WATSON, R.J. ET AL., TETRAHEDRON LETT., (2002), vol. 43, pages 683 - 685
 US19600613666
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.